Follow
IVAN MARQUEZ RODAS (ORCID: 0000-0002-2476-668X)
IVAN MARQUEZ RODAS (ORCID: 0000-0002-2476-668X)
Instituto de Investigación Sanitaria Gregorio Marañón
Verified email at salud.madrid.org
Title
Cited by
Cited by
Year
Combined nivolumab and ipilimumab or monotherapy in untreated melanoma
J Larkin, V Chiarion-Sileni, R Gonzalez, JJ Grob, CL Cowey, CD Lao, ...
New England journal of medicine 373 (1), 23-34, 2015
78572015
Overall survival with combined nivolumab and ipilimumab in advanced melanoma
JD Wolchok, V Chiarion-Sileni, R Gonzalez, P Rutkowski, JJ Grob, ...
New England Journal of Medicine 377 (14), 1345-1356, 2017
35232017
Five-year survival with combined nivolumab and ipilimumab in advanced melanoma
J Larkin, V Chiarion-Sileni, R Gonzalez, JJ Grob, P Rutkowski, CD Lao, ...
New England journal of medicine 381 (16), 1535-1546, 2019
30032019
Adjuvant nivolumab versus ipilimumab in resected stage III or IV melanoma
J Weber, M Mandala, M Del Vecchio, HJ Gogas, AM Arance, CL Cowey, ...
New England Journal of Medicine 377 (19), 1824-1835, 2017
21842017
Nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone in advanced melanoma (CheckMate 067): 4-year outcomes of a multicentre, randomised, phase 3 trial
FS Hodi, V Chiarion-Sileni, R Gonzalez, JJ Grob, P Rutkowski, CL Cowey, ...
The Lancet Oncology 19 (11), 1480-1492, 2018
13382018
Dabrafenib plus trametinib in patients with BRAFV600-mutant melanoma brain metastases (COMBI-MB): a multicentre, multicohort, open-label, phase 2 trial
MA Davies, P Saiag, C Robert, JJ Grob, KT Flaherty, A Arance, ...
The Lancet Oncology 18 (7), 863-873, 2017
7042017
Long-term outcomes with nivolumab plus ipilimumab or nivolumab alone versus ipilimumab in patients with advanced melanoma
JD Wolchok, V Chiarion-Sileni, R Gonzalez, JJ Grob, P Rutkowski, ...
Journal of Clinical Oncology 40 (2), 127, 2022
5892022
Efficacy and safety of nivolumab alone or in combination with ipilimumab in patients with mucosal melanoma: a pooled analysis
SP D’Angelo, J Larkin, JA Sosman, C Lebbé, B Brady, B Neyns, ...
Journal of Clinical Oncology 35 (2), 226, 2017
5422017
Adjuvant nivolumab versus ipilimumab in resected stage IIIB–C and stage IV melanoma (CheckMate 238): 4-year results from a multicentre, double-blind, randomised, controlled …
PA Ascierto, M Del Vecchio, M Mandalá, H Gogas, AM Arance, S Dalle, ...
The Lancet Oncology 21 (11), 1465-1477, 2020
4332020
Prophylactic TNF blockade uncouples efficacy and toxicity in dual CTLA-4 and PD-1 immunotherapy
E Perez-Ruiz, L Minute, I Otano, M Alvarez, MC Ochoa, V Belsue, ...
Nature 569 (7756), 428-432, 2019
3562019
Evaluation of two dosing regimens for nivolumab in combination with ipilimumab in patients with advanced melanoma: results from the phase IIIb/IV CheckMate 511 trial
C Lebbé, N Meyer, L Mortier, I Marquez-Rodas, C Robert, P Rutkowski, ...
Journal of Clinical Oncology 37 (11), 867, 2019
3122019
Interferon gamma, an important marker of response to immune checkpoint blockade in non-small cell lung cancer and melanoma patients
N Karachaliou, M Gonzalez-Cao, G Crespo, A Drozdowskyj, E Aldeguer, ...
Therapeutic advances in medical oncology 10, 1758834017749748, 2018
2512018
ESMO consensus conference recommendations on the management of metastatic melanoma: under the auspices of the ESMO Guidelines Committee
U Keilholz, PA Ascierto, R Dummer, C Robert, P Lorigan, A Van Akkooi, ...
Annals of oncology 31 (11), 1435-1448, 2020
1672020
Participation of prostacyclin in endothelial dysfunction induced by aldosterone in normotensive and hypertensive rats
J Blanco-Rivero, V Cachofeiro, V Lahera, R Aras-Lopez, ...
Hypertension 46 (1), 107-112, 2005
1602005
Nivolumab for patients with advanced melanoma treated beyond progression: analysis of 2 phase 3 clinical trials
GV Long, JS Weber, J Larkin, V Atkinson, JJ Grob, D Schadendorf, ...
JAMA oncology 3 (11), 1511-1519, 2017
1592017
Efficacy of neoadjuvant carboplatin plus docetaxel in triple-negative breast cancer: combined analysis of two cohorts
P Sharma, S López-Tarruella, JA García-Saenz, C Ward, CS Connor, ...
Clinical cancer research 23 (3), 649-657, 2017
1402017
CheckMate 067: 6.5-year outcomes in patients (pts) with advanced melanoma.
JD Wolchok, V Chiarion-Sileni, R Gonzalez, JJ Grob, P Rutkowski, ...
Journal of Clinical Oncology 39 (15_suppl), 9506-9506, 2021
1202021
Deregulated miRNAs in Hereditary Breast Cancer Revealed a Role for miR-30c in Regulating KRAS Oncogene
M Tanic, K Yanowsky, C Rodriguez-Antona, R Andrés, I Márquez-Rodas, ...
PloS one 7 (6), e38847, 2012
1142012
Immunotherapeutic effects of intratumoral nanoplexed poly I: C
MA Aznar, L Planelles, M Perez-Olivares, C Molina, S Garasa, I Etxeberría, ...
Journal for immunotherapy of cancer 7, 1-16, 2019
1102019
Pathological response and survival in triple-negative breast cancer following neoadjuvant carboplatin plus docetaxel
P Sharma, S López-Tarruella, JA García-Saenz, QJ Khan, HL Gómez, ...
Clinical Cancer Research 24 (23), 5820-5829, 2018
1102018
The system can't perform the operation now. Try again later.
Articles 1–20